10/09/2026
When a measles specimen reaches the lab, one detail can change how the result is interpreted: when it was collected.
CDC’s October 2 update reported 3,887 confirmed U.S. measles cases in 2026 as of October 1, with 95% linked to outbreaks.
For laboratory teams, that puts specimen timing, handling, and testing strategy in focus.
Real-time RT-PCR and serum IgM testing provide complementary information. IgM may be negative early after rash onset, while a negative RT-PCR result may not rule out infection when specimen timing or quality is suboptimal.
The questions extend beyond detection. In measles-related research, distinguishing vaccine from wild-type strains—or investigating measles and rubella together—may also be relevant.
BP LabLine carries BioPerfectus real-time PCR assays for both research applications. Details are in the comments.
For Research Use Only. Not for use in diagnostic procedures or patient testing.
For clinical and public health laboratory teams: which step creates the most friction in your workflow—collection, transport, or testing?
Source: CDC | Data as of October 1, 2026; preliminary and subject to change.
MMR vaccination remains the best protection against measles.